7.67
Schlusskurs vom Vortag:
$7.73
Offen:
$7.72
24-Stunden-Volumen:
269.59K
Relative Volume:
1.62
Marktkapitalisierung:
$163.96M
Einnahmen:
$66.59M
Nettoeinkommen (Verlust:
$-104.93M
KGV:
-1.5495
EPS:
-4.95
Netto-Cashflow:
$-96.48M
1W Leistung:
+16.39%
1M Leistung:
+6.82%
6M Leistung:
+48.07%
1J Leistung:
-47.75%
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Firmenname
Enanta Pharmaceuticals Inc
Sektor
Branche
Telefon
617 607 0800
Adresse
4 KINGSBURY AVENUE, WATERTOWN, MA
Vergleichen Sie ENTA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ENTA
Enanta Pharmaceuticals Inc
|
7.67 | 140.87M | 66.59M | -104.93M | -96.48M | -4.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-08-09 | Herabstufung | JP Morgan | Neutral → Underweight |
2023-08-08 | Herabstufung | Jefferies | Buy → Hold |
2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
2022-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
2022-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
2021-10-07 | Eingeleitet | Jefferies | Buy |
2021-09-09 | Eingeleitet | SVB Leerink | Mkt Perform |
2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
2020-11-24 | Eingeleitet | Evercore ISI | Underperform |
2020-08-28 | Fortgesetzt | ROTH Capital | Buy |
2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
2020-07-27 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
2020-03-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
2019-11-22 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2019-09-26 | Herabstufung | JP Morgan | Neutral → Underweight |
2019-05-24 | Eingeleitet | Wolfe Research | Outperform |
2019-04-23 | Hochstufung | Berenberg | Hold → Buy |
2018-12-13 | Eingeleitet | Berenberg | Hold |
2018-06-06 | Eingeleitet | ROTH Capital | Buy |
2018-02-08 | Herabstufung | JP Morgan | Overweight → Neutral |
2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2017-11-21 | Bestätigt | RBC Capital Mkts | Outperform |
2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
2017-07-11 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
2016-04-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2016-02-09 | Bestätigt | Barclays | Underweight |
2015-10-23 | Herabstufung | Barclays | Equal Weight → Underweight |
2015-10-23 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
Alle ansehen
Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten
What drives Enanta Pharmaceuticals Inc. stock priceTriple-digit growth rates - Autocar Professional
What analysts say about Enanta Pharmaceuticals Inc. stockPhenomenal wealth increase - jammulinksnews.com
Is Enanta Pharmaceuticals Inc. a good long term investmentHigh-yield capital appreciation - jammulinksnews.com
Enanta Pharmaceuticals Inc. Stock Analysis and ForecastConsistent wealth multiplication - jammulinksnews.com
Enanta Pharmaceuticals at Baird’s Biotech: Strategic Virology and Immunology Shift - Investing.com Canada
why enanta pharmaceuticals inc. stock attracts strong analyst attentionShort Term Risk Controlled Alerts - Newser
Will Enanta Pharmaceuticals Inc. stock benefit from interest rate changesFast Growing Stocks - Newser
Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series - BioSpace
how enanta pharmaceuticals inc. stock performs during market volatilityFree Smart Investment Opportunities - Newser
What makes Enanta Pharmaceuticals Inc. stock price move sharplyBreakout Momentum Stocks - Newser
How Enanta Pharmaceuticals Inc. stock performs during market volatilityFree Investment Community - Newser
Why Enanta Pharmaceuticals Inc. stock attracts strong analyst attentionVolume Spike Monitors - Newser
(ENTA) On The My Stocks Page - news.stocktradersdaily.com
Enanta Pharmaceuticals Insider Buyers Net US$65k Despite 11% Stock Decline - simplywall.st
(ENTA) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Enanta Pharmaceuticals’ SWOT analysis: stock shifts focus to immunology amid RSV progress - Investing.com Nigeria
ENTA’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga
FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga
AbbVie wins FDA nod for Mavyret label expansion (ABBV:NYSE) - Seeking Alpha
Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approva - GuruFocus
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Yahoo Finance
(ENTA) Proactive Strategies - news.stocktradersdaily.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $24.00 Price Target at JMP Securities - Defense World
Enanta Pharma (ENTA) Receives Target Price Boost from JMP Securi - GuruFocus
Enanta (ENTA) Price Target Raised as Key Clinical Results Antici - GuruFocus
Enanta (ENTA) Price Target Raised as Key Clinical Results Anticipated | ENTA Stock News - GuruFocus
Citizens JMP raises Enanta Pharmaceuticals stock price target to $24 By Investing.com - Investing.com UK
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - BioSpace
Finanzdaten der Enanta Pharmaceuticals Inc-Aktie (ENTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):